◆ mixed
Impact
PhaseApproved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
Time to marketAlready on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
ZYNLONTA loncastuximab tesirine Updated Nov 11
What to watch
Watch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.
Bull case
- ZYNLONTA product revenue grew 33% YoY to $21M in Q3 2026, the fourth straight quarter ahead of consensus, showing commercial traction in its approved indication
- Cash runway extended into 2029 after an $86.6M PIPE from healthcare-focused investors (Redmile, TCG Crossover, Bain Capital Life Sciences) and debt refinancing, removing near-term financing risk
- LOTIS-7 (ZYNLONTA + bispecific antibody) showed no dose-limiting toxicities or high-grade CRS/ICANS in initial data, suggesting a potentially safer combination path
Bear case
- LOTIS-5 confirmatory trial showed a 13% death rate in the ZYNLONTA + rituximab arm, causing shares to drop ~50% and the FDA to cite 'significant concerns' about the combination regimen
- The path to full FDA approval is now uncertain; the company is evaluating alternatives after the pre-sBLA meeting, and the accelerated approval could be at risk if a confirmatory path is not agreed upon
- Competition in DLBCL is intense: CAR-T therapies (Yescarta, Breyanzi), bispecific antibodies (Glofitamab, Epcoritamab), and other ADCs all target the same patient population